# AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL

> **NCT07717177** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 112 (estimated)

## Conditions studied

- Large B-Cell Lymphoma (LBCL)

## Interventions

- **DRUG:** Polatuzumab Vedotin
- **DRUG:** Rituximab (R)
- **DRUG:** Zanubrutinib
- **DRUG:** Lenalidomide
- **DRUG:** Glofitamab

## Key facts

- **NCT ID:** NCT07717177
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-30
- **Primary completion:** 2029-06-30
- **Final completion:** 2029-12-31
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2026-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07717177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07717177, "AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07717177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*